154 related articles for article (PubMed ID: 6291192)
1. Inhibitory mechanism of dipyridamole on platelet aggregation ex vivo.
Fukawa K; Saitoh K; Irino O; Ohkubo K; Hashimoto S
Thromb Res; 1982 Aug; 27(3):333-40. PubMed ID: 6291192
[TBL] [Abstract][Full Text] [Related]
2. Cilostazol and dipyridamole synergistically inhibit human platelet aggregation.
Liu Y; Cone J; Le SN; Fong M; Tao L; Shoaf SE; Bricmont P; Czerwiec FS; Kambayashi J; Yoshitake M; Sun B
J Cardiovasc Pharmacol; 2004 Aug; 44(2):266-73. PubMed ID: 15243309
[TBL] [Abstract][Full Text] [Related]
3. Effects of SK&F 94120, an inhibitor of cyclic nucleotide phosphodiesterase type III, on human platelets.
Simpson AW; Reeves ML; Rink TJ
Biochem Pharmacol; 1988 Jun; 37(12):2315-20. PubMed ID: 2455518
[TBL] [Abstract][Full Text] [Related]
4. Dipyridamole inhibits platelet aggregation in whole blood.
Gresele P; Zoja C; Deckmyn H; Arnout J; Vermylen J; Verstraete M
Thromb Haemost; 1983 Dec; 50(4):852-6. PubMed ID: 6665766
[TBL] [Abstract][Full Text] [Related]
5. Effect of adenyl-cyclase activators, phosphodiesterase inhibitors and pyridoxal-5-phosphate on platelet aggregation and adenosine-3'-5'-cyclic monophosphate accumulation.
Zahavi M; Zahavi J; Kakkar VV
Thromb Haemost; 1984 Oct; 52(2):205-9. PubMed ID: 6098048
[TBL] [Abstract][Full Text] [Related]
6. Differential effects of phosphodiesterase inhibitors on platelet activating factor (PAF)- and adenosine diphosphate (ADP)-induced equine platelet aggregation.
Rickards KJ; Andrews MJ; Waterworth TH; Alexander GB; Cunningham FM
J Vet Pharmacol Ther; 2003 Aug; 26(4):277-82. PubMed ID: 12887610
[TBL] [Abstract][Full Text] [Related]
7. Effect of dipyridamole and its monoglucuronide derivative on adenosine uptake by human platelets and ADP-induced platelet aggregation.
Subbarao K; Rucinski B; Niewiarowski S
Biochem Pharmacol; 1977 May; 26(9):906-7. PubMed ID: 861060
[No Abstract] [Full Text] [Related]
8. Synergistic platelet inhibitory effect of the phosphodiesterase inhibitor piroximone and iloprost.
Buerke M; Dieterich HA; Meyer J; Darius H
Agents Actions Suppl; 1992; 37():71-7. PubMed ID: 1378692
[TBL] [Abstract][Full Text] [Related]
9. [Effect of trapidil and papaverine on thrombocyte aggregation and phosphodiesterase activity].
Glusa E
Farmakol Toksikol; 1986; 49(6):48-9. PubMed ID: 3028860
[TBL] [Abstract][Full Text] [Related]
10. Effect of dipyridamole-like compound (R-E 244) on aggregation and cyclic AMP accumulation in human platelets.
Söderbäck U; Sollevi A
Thromb Res; 1991 Nov; 64(3):355-62. PubMed ID: 1666697
[TBL] [Abstract][Full Text] [Related]
11. Estimation of anti-platelet drugs on human platelet aggregation with a novel whole blood aggregometer by a screen filtration pressure method.
Sudo T; Ito H; Ozeki Y; Kimura Y
Br J Pharmacol; 2001 Aug; 133(8):1396-404. PubMed ID: 11498527
[TBL] [Abstract][Full Text] [Related]
12. Specific inhibition of ADP-induced platelet aggregation by clopidogrel in vitro.
Weber AA; Reimann S; Schrör K
Br J Pharmacol; 1999 Jan; 126(2):415-20. PubMed ID: 10077233
[TBL] [Abstract][Full Text] [Related]
13. Potentiation of the antiplatelet action of adenosine in whole blood by dipyridamole or dilazep and the cAMP phosphodiesterase inhibitor, RA 233.
Dawicki DD; Agarwal KC; Parks RE
Thromb Res; 1986 Jul; 43(2):161-75. PubMed ID: 3016942
[TBL] [Abstract][Full Text] [Related]
14. The effects of siguazodan, a selective phosphodiesterase inhibitor, on human platelet function.
Murray KJ; England PJ; Hallam TJ; Maguire J; Moores K; Reeves ML; Simpson AW; Rink TJ
Br J Pharmacol; 1990 Mar; 99(3):612-6. PubMed ID: 2158847
[TBL] [Abstract][Full Text] [Related]
15. The effect of SK&F 95654, a novel phosphodiesterase inhibitor, on cardiovascular, respiratory and platelet function.
Murray KJ; Eden RJ; Dolan JS; Grimsditch DC; Stutchbury CA; Patel B; Knowles A; Worby A; Lynham JA; Coates WJ
Br J Pharmacol; 1992 Oct; 107(2):463-70. PubMed ID: 1422592
[TBL] [Abstract][Full Text] [Related]
16. Interplay between milrinone and adenosine in the inhibition of human platelet response.
Anfossi G; Massucco P; Piretto V; Mularoni E; Cavalot F; Mattiello L; Trovati M
Gen Pharmacol; 1996 Oct; 27(7):1149-54. PubMed ID: 8981060
[TBL] [Abstract][Full Text] [Related]
17. Dipyridamole synergizes with nitric oxide to prolong inhibition of thrombin-induced platelet shape change.
Jensen BO; Kleppe R; Kopperud R; Nygaard G; Døskeland SO; Holmsen H; Selheim F
Platelets; 2011; 22(1):8-19. PubMed ID: 20958117
[TBL] [Abstract][Full Text] [Related]
18. Potentiation of antiaggregating activity of adenosine by a phosphodiesterase inhibitor, EG626 (oxagrelate), in human platelets in vitro.
Azuma H; Takashima Y; Ishikawa M; Yamakado T
Jpn J Pharmacol; 1984 Feb; 34(2):159-70. PubMed ID: 6205194
[TBL] [Abstract][Full Text] [Related]
19. Role of plasma adenosine in the antiplatelet action of HL 725, a potent inhibitor of cAMP phosphodiesterase: species differences.
Agarwal KC; Buckley RS; Parks RE
Thromb Res; 1987 Jul; 47(2):191-200. PubMed ID: 2821650
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of platelet aggregation in whole blood by dipyridamole and aspirin.
Heptinstall S; Fox S; Crawford J; Hawkins M
Thromb Res; 1986 Apr; 42(2):215-23. PubMed ID: 3715801
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
